Abstract
Epigenetic regulations play an important role in disease development. In this study, we have investigated epigenetic regulations in restrictive cardiomyopathy mice with cTnI 193His mutation. Our results demonstrated that phosphodiesterase (PDEs) 4d was down-regulated in the heart of these mice. Further studies showed that the epigenetic modifications were associated with enhanced acetylation of histone 3 lysine 4 and lysines 9, whereas tri-methylation of histone 3 lysine 4, were decreased in histones near the PDE4d gene promoter regions. The binding levels of histone transmethylase SMYD1 and histone deacetylase HDAC1 were increased in the gene promoter regions in cTnI193His transgenic hearts. Using immune-fluorescent labeling we found an evidence of cTnI existence in the nucleus of cardiomyocytes and Western blotting further confirmed that both wild type and mutated cTnI could be detected in the cell nucleus of the hearts. Furthermore, an interaction between cTnI and SMYD1, or cTnI and HDAC1 was observed. Overexpression of the mutated cTnI in cultured cardiomyocytes reduced the expression of PDE4d. Our data suggest that the decrease of PDE4d expression in RCM mice caused by cTnI mutations may be related to epigenetic regulation, i.e., histone acetylation and methylation, and cTnI might be involved in this procedure via an interaction with HDAC1 and SMAD1 in the hearts.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Asrih, M., and Steffens, S. (2013). Emerging role of epigenetics and miRNA in diabetic cardiomyopathy. Cardiovasc Pathol 22, 117–125.
Asumda, F.Z., and Chase, P.B. (2012). Nuclear cardiac troponin and tropomyosin are expressed early in cardiac differentiation of rat mesenchymal stem cells. Differentiation 83, 106–115.
Beavo, J.A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75, 725–743.
Bergmann, O., Zdunek, S., Alkass, K., Druid, H., Bernard, S., and Frisén, J. (2011). Identification of cardiomyocyte nuclei and assessment of ploidy for the analysis of cell turnover. Exp Cell Res 317, 188–194.
Fischmeister, R., Castro, L.R.V., Abi-Gerges, A., Rochais, F., Jurevicius, J., Leroy, J., and Vandecasteele, G. (2006). Compartmentation of cyclic nucleotide signaling in the heart. Circ Res 99, 816–828.
Florescu, C., Rogoveanu, I., Vere, C.C., Târtea, G.C., Târtea, E.A., and Mogoantă, L. (2016). From molecular mechanism to morphological changes in cardiomyopathy. Rom J Morphol Embryol 57, 1207–1214.
Fu, Q., Wang, Q., and Xiang, Y.K. (2017). Insulin and β adrenergic receptor signaling: crosstalk in heart. Trends Endocrinol Metab 28, 416–427.
Haas, J., Frese, K.S., Park, Y.J., Keller, A., Vogel, B., Lindroth, A.M., Weichenhan, D., Franke, J., Fischer, S., Bauer, A., et al. (2013). Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med 5, 413–429.
Kajstura, J., Urbanek, K., Perl, S., Hosoda, T., Zheng, H., Ogorek, B., Ferreira-Martins, J.., Goichberg, P., Rondon-Clavo, C., Sanada, F., et al. (2010). Cardiomyogenesis in the adult human heart. Circ Res 107, 305–315.
Kimura, A. (2015). Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet 61, 41–50.
Li, Y., Zhang, L., Jean-Charles, P.Y., Nan, C., Chen, G., Tian, J., Jin, J.P., Gelb, I.J., and Huang, X. (2013). Dose-dependent diastolic dysfunction and early death in a mouse model with cardiac troponin mutations. J Mol Cell Cardiol 62, 227–236.
Liu, Y., Chen, W., Gaudet, J., Cheney, M.D., Roudaia, L., Cierpicki, T., Klet, R.C., Hartman, K., Laue, T.M., Speck, N.A., et al. (2007). Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO’s activity. Cancer Cell 11, 483–497.
Lugnier, C. (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Therapeutics 109, 366–398.
Marian, A.J., van Rooij, E., and Roberts, R. (2016). Genetics and genomics of single-gene cardiovascular diseases. J Am Coll Cardiol 68, 2831–2849.
Masselink, H., and Bernards, R. (2000). The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of NCoR. Oncogene 19, 1538–1546.
Monserrat, L., Ortiz-Genga, M., Lesende, I., Garcia-Giustiniani, D., Barriales-Villa, R., Una-Iglesias, D., Syrris, P., and Castro-Beiras, A. (2015). Genetics of cardiomyopathies: novel perspectives with next generation sequencing. CPD 21, 418–430.
Morimoto, S. (2008). Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res 77, 659–666.
Omori, K., and Kotera, J. (2007). Overview of PDEs and their regulation. Circ Res 100, 309–327.
Paige, S.L., Thomas, S., Stoick-Cooper, C.L., Wang, H., Maves, L., Sandstrom, R., Pabon, L., Reinecke, H., Pratt, G., Keller, G., et al. (2012). A temporal chromatin signature in human embryonic stem cells identifies regulators of cardiac development. Cell 151, 221–232.
Pan, B., Xu, Z.W., Xu, Y., Liu, L.J., Zhu, J., Wang, X., Nan, C., Zhang, Z., Shen, W., Huang, X.P., et al. (2016). Diastolic dysfunction and cardiac troponin I decrease in aging hearts. Archives Biochem Biophys 603, 20–28.
Rindler, T.N., Hinton, R.B., Salomonis, N., and Ware, S.M. (2017). Molecular characterization of pediatric restrictive cardiomyopathy from integrative genomics. Sci Rep 7, 39276.
Sahota, V.K., Grau, B.F., Mansilla, A., and Ferrús, A. (2009). Troponin I and Tropomyosin regulate chromosomal stability and cell polarity. J Cell Sci 122, 2623–2631.
Stewart, M.D., Lopez, S., Nagandla, H., Soibam, B., Benham, A., Nguyen, J., Valenzuela, N., Wu, H.J., Burns, A.R., Rasmussen, T.L., et al. (2016). Mouse myofibers lacking the SMYD1 methyltransferase are susceptible to atrophy, internalization of nuclei and myofibrillar disarray. Dis Model Mech 9, 347–359.
Tobacman, L.S. (1996). Thin filament-mediated regulation of cardiac contraction. Annu Rev Physiol 58, 447–481.
Varian, K., and Tang, W.H.W. (2017). Therapeutic strategies targeting inherited cardiomyopathies. Curr Heart Fail Rep 14, 321–330.
Wu, H., Lee, J., Vincent, L.G., Wang, Q., Gu, M., Lan, F., Churko, J.M., Sallam, K.I., Matsa, E., Sharma, A., et al. (2015). Epigenetic regulation of phosphodiesterases 2A and 3A underlies compromised β-adrenergic signaling in an iPSC model of dilated cardiomyopathy. Cell Stem Cell 17, 89–100.
Xu, Y., Liu, L., Pan, B., Zhu, J., Nan, C., Huang, X., and Tian, J. (2015). DNA methylation regulates mouse cardiac myofibril gene expression during heart development. J Biomed Sci 22, 88.
Zaccolo, M., and Movsesian, M.A. (2007). cAMP and cGMP signaling cross-talk. Circulation Res 100, 1569–1578.
Zhao, C.Y., Greenstein, J.L., and Winslow, R.L. (2015). Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway. J Mol Cell Cardiol 88, 29–38.
Zhao, W., Liu, L., Pan, B., Xu, Y., Zhu, J., Nan, C., Huang, X., and Tian, J. (2015). Epigenetic regulation of cardiac myofibril gene expression during heart development. Cardiovasc Toxicol 15, 203–209.
Zheng, H., Huang, H., Ji, Z., Yang, Q., Yu, Q., Shen, F., Liu, C., and Xiong, F. (2016). A double heterozygous mutation of TNNI3 causes hypertrophic cardiomyopathy in a Han Chinese family. Cardiology 133, 91–96.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (81700214).
Author information
Authors and Affiliations
Corresponding author
Additional information
Compliance and ethics
The author(s) declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Zhao, W., Wu, X., Wang, Z. et al. Epigenetic regulation of phosphodiesterase 4d in restrictive cardiomyopathy mice with cTnI mutations. Sci. China Life Sci. 63, 563–570 (2020). https://doi.org/10.1007/s11427-018-9463-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-018-9463-9